Ultime notizie per Privia Health Gr (NASDAQ:PRVA) Azioni

Privia Health Gr

Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.

Privia Health Group

Privia Health Group Inc

B of A Securities analyst Geoff Meacham upgrades Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) from Neutral to Buy and raises the price target from $22 to $31.

News

Upgrades

Price Target

Analyst Ratings

TYRA

B of A Securities Upgrades Tyra Biosciences to Buy, Raises Price Target to $31

Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.53 by 79.25 percent. The company reported quarterly sales of $2.058 billion which beat the analyst consensus estimate of $2.030 billion by 1.37 percent. This is a 1.08 percent increase over sales of $2.036 billion the same period last year.

Earnings

Earnings Beats

ALLY

Ally Financial Q3 2024 Adj. EPS $0.95 Beats $0.53 Estimate, Sales $2.058B Beat $2.030B Estimate

Keybanc analyst Eric Gonzalez maintains Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Overweight and lowers the price target from $37 to $36.

Keybanc Maintains Overweight on Dine Brands Global, Lowers Price Target to $36

Keybanc analyst Eric Heath maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Overweight and raises the price target from $310 to $340.

CYBR

Keybanc Maintains Overweight on CyberArk Software, Raises Price Target to $340

B of A Securities analyst Ross Gilardi downgrades Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) from Neutral to Underperform and maintains the price target from $26 to $26.

Downgrades

B of A Securities Downgrades Kennametal to Underperform, Maintains Price Target to $26

Wall Street is priming for a positive start on Friday after the major averages ended narrowly mixed in the previous session. <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">Positive reaction</a> to Netflix, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) earnings could provide a lift to the tech space, given earnings news flow from the sector will likely start in earnest next week. Earnings and speeches by Federal Reserve officials could set the tempo for Friday&#8217;s session. China&#8217;s third-quarter GDP rose slightly more than estimates, allaying the fears of traders. Gold continues to make record after record, while oil continues to have a volatile ride amid geopolitical tensions.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.39%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.17%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.03%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.46%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.23% to $583.61 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) jumped 0.51% to $493.75, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks closed narrowly mixed as traders digested a batch of mixed economic data as well as a flurry of earnings. After opening higher, the major indices experienced some volatility in the morning, although holding mostly above the unchanged line. 
Stocks gave back most of their gains in late afternoon trading before finishing on a mixed note. 
The Dow Industrials closed at fresh intraday and closing highs, thanks to a positive reaction to Travelers Companies, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) earnings, while the S&amp;P 500 Index hit an intraday high before squandering all the gains and closing marginally lower.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+0.04%</td>
<td>18,373.61</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+0.02%</td>
<td>5,841.47</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+0.37%</td>
<td>43,239.05</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.25%</td>
<td>2,280.85</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
After separate reports showed strong September retail sales growth, jobless claims, which fell after Hurricane Helene&#8217;s impact wore off, and a decline in industrial production amid the Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) strike, Comerica Chief Economist Bill Adams said, &#8220;The economy is in pretty good shape.&#8221; &#8220;Since consumer spending fuels two-thirds of U.S. demand, the economy can't be doing too bad as long as consumers still have their pocketbooks open,&#8221; he said.
The economist expects the Hurricanes that devastated swathes of the Southeast in late September and early October to be a big drag on releases for October.&nbsp;This will make it difficult to read the underlying trend accurately, he said.
Calling the headwinds temporary, Adams said, &#8220;With the Fed expected to continue lowering interest rates through the turn of the year, credit-sensitive sectors of the economy should perk up in coming quarters, sustaining the economic expansion into 2025.&#8221;
See Also:<a href="https://www.benzinga.com/money/best-strategies-for-futures-trading"> Best Futures Trading Strategies in 2024</a>
Upcoming Economic Data:
<ul>
<li>The Commerce Department will release the housing starts report for September at 8:30 a.m. EDT. Economists, on average, estimate housing starts to come in at a seasonally adjusted annual rate of 1.35 million units, slightly down from the 1.36-million-unit rate in August. Building permits, an indicator of future housing starts may have declined from 1.48 million units to 1.45 million units.</li>
<li>Among the Fed speakers scheduled for the day are:
<ul>
<li>Atlanta Fed president Raphael Bostic: 9:30 a.m. EDT</li>
<li>Minneapolis Fed President Neel Kashkari: 10 a.m. EDT</li>
<li>Fed Governor Christopher Waller is due to speak at 12:10 p.m. EDT.</li>
</ul>
</li>
<li>The Atlanta Fed&#8217;s GDPNow data for the third quarter will be released at 10:30 a.m. EDT.</li>
</ul>
Stocks In Focus:
<ul>
<li>Netflix climbed about 5.75% <a href="https://www.benzinga.com/premarket">in premarket trading</a> following the streaming giant&#8217;s quarterly results.</li>
<li>Among the other stocks moving on earnings are Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) (up nearly 7%), and Western Alliance Bancorporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) (down over 5.25%.</li>
<li>Ally Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>), Autoliv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>), Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>), Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), Regions Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) and Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) and American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) are among the noteworthy <a href="https://www.benzinga.com/calendars/earnings">companies reporting ahead of the market opening</a>.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) fell over 10% after the Wall Street Journal reported that the company is naming longtime executive David Joyner as its new chief, succeeding Karen Lynch.</li>
<li>Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) fell over 6% on a negative analyst action.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures pulled back modestly but gold futures gained ground as they scaled a fresh record. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) added over 1.50% over the past 24 hours and traded just under the $68K mark.
The 10-year U.S. Treasury note yield was little changed at 4.097%.
Asian stocks closed mostly higher, led by China and Hong Kong, which rallied on the back of the Chinese third-quarter GDP data. The Japanese market benefited from the yen&#8217;s weakness. The European Central Bank&#8217;s rate cut also buoyed sentiment.
The European markets also advanced in early trading, although the U.K. market was experiencing some weakness.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41397978/hedge-fund-billionaire-daniel-loeb-bets-on-trump-win-singles-out-this-recent-buy-as">Hedge Fund Billionaire Daniel Loeb Bets On Trump Win, Singles Out This Recent Buy As Having &#8216;Significant Upside Potential&#8217;</a></li>
</ul>
Image Via Shutterstock

Equities

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

COHR

FITB

ISRG

NFLX

US Stocks Set To End Week Strong As Netflix Q3 Earnings Boost Optimism, Gold Hits New Highs: What's Driving Sentiment Friday?

Amer Sports Says It Acknowledges Ruling Issued By Oslo District Court Which Prohibits It From Selling Some Products In Norwegian Market; Company Says It Disagrees With Ruling & Will Be Appealing Court's Decision

DoE Selects Consumers Energy To Receive Nearly $20M Financial Assistance Award To Deploy New Technology And Provide Real-time Visibility Into Grid

Apple Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) iPhone 16 scored a win in China in its first three weeks, highlighting the rising demand for luxury smartphones paired with artificial intelligence features. China is a crucial market for the company.
The iPhone 16 performance coincided with China&#8217;s stimulus plans and the upcoming holiday season.
Apple&#8217;s latest smartphone model clocked a sales growth of 20% year-on-year in their first three weeks, beating the iPhone 15, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-10-18/apple-iphone-16-sales-soar-20-in-china-debut-as-demand-recovers?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">cites</a> Counterpoint Research data.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41143369/apple-to-launch-budget-iphone-in-2025-aims-for-market-share-gains-from-huawei-and-xiaomi" rel="noreferrer noopener">Apple To Launch Budget iPhone in 2025, Aims for Market Share Gains from Huawei and Xiaomi</a>
The shift to the premium models fueled sales of the top-end Pro and Pro Max models by 44% year-on-year.
Counterpoint&#8217;s&nbsp;Ivan Lam attributed the iPhone 15&#8217;s weak initial response to production issues and competition from&nbsp;Huawei Technologies Co&#8217;s Mate 60 series.
However, challenges continue to lurk for iPhones from China&#8217;s domestic companies, like&nbsp;Vivo&#8217;s X200 Pro flagship, Huawei&#8217;s next-generation Mate device, and&nbsp;Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) and&nbsp;Oppo&#8217;s upcoming offerings.
Lam also flagged the postponement of purchases by Chinese consumers until November&#8217;s Singles&#8217; Day to avail themselves of discounts from Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)&nbsp;and&nbsp;JD.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>).
Separate reports indicated Chinese online retailers PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) Pinduoduo and Alibaba&#8217;s Taobao doled out discounts on the iPhone 16 series ahead of its official release due to its <a target="_blank" href="https://www.benzinga.com/news/24/09/40785959/iphone-16-fails-to-sway-some-chinese-buyers-im-going-to-buy-huaweis-tri-fold-phone-missing-ai-featur" rel="noreferrer noopener">lack of AI features</a>, which will likely roll out for Chinese users in 2025.
Pinduoduo started selling the iPhone 16 Plus with 512 gigabytes of storage at a 10% discount from the official price. The 128GB iPhone 16 is being sold at an even steeper 11% discount.
Both Pinduoduo and Taobao marketplace have slapped a 4% discount on the 256GB version of the high-end iPhone 16 Pro Max. Tmall shopping platform also offers buyers the option to pay for a new Apple handset in 24 instalments without interest charges.
Kuo Ming-chi of TF International Securities <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3278855/apples-iphone-16-already-selling-discount-china-ai-delay-cools-demand" rel="noreferrer noopener">told</a> SCMP that the global pre-order sales for the iPhone 16 are down 13% compared to last year&#8217;s iPhone 15 launch, partly due to the absence of Apple Intelligence and intense competition in China.
International Data Corporation (IDC)&nbsp;had <a target="_blank" href="https://www.benzinga.com/news/24/08/40600289/apples-market-share-poised-to-gain-genai-and-iphone-16-lead-the-way-idc" rel="noreferrer noopener">projected a recovery</a> in the smartphone market, which was hampered by the supply chain crisis fueled by the 2020 pandemic outbreak in China.
IDC pointed to the success of generative AI in the upcoming iPhone 16 and Apple&#8217;s ability to establish local AI partnerships in China as potential growth factors. It forecasts that GenAI smartphones will capture 18% of the market by 2024, fueled by premium device trends.
Apple stock gained 39% in the last six months. Investors can gain exposure to the stock through Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) and Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
Price Action: AAPL stock traded higher by 1.79% at $236.30 premarket at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41388050/apples-3nm-push-boosts-taiwan-semis-q3-ai-revenue-set-to-triple-analyst" target="_blank" rel="noreferrer noopener">Apple&#8217;s 3nm Push Boosts Taiwan Semi&#8217;s Q3, AI Revenue Set To Triple: Analyst</a></li>
</ul>
Photo courtesy: Apple

Government

Emerging Markets

Tech

Media

AAPL

BABA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XIACF

XIACY

Apple iPhone 16 Sees 20% Sales Surge in China, But AI Absence Prompts Early Price Cuts

HC Wainwright &amp; Co. analyst Sean Lee reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and maintains $7 price target.

Reiteration

VSTM

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $7 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and maintains $22 price target.

DCTH

HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $22 Price Target

B of A Securities analyst Vivek Arya maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $165 to $190.

NVDA

B of A Securities Maintains Buy on NVIDIA, Raises Price Target to $190

BMO Capital analyst Fadi Chamoun downgrades Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) from Outperform to Market Perform and lowers the price target from $214 to $210.

ODFL

BMO Capital Downgrades Old Dominion Freight Line to Market Perform, Lowers Price Target to $210

On Friday, CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) appointed longtime executive David Joyner as its new president and CEO, replacing Karen Lynch amid the company&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398693/cvs-health-appoints-david-joyner-president-and-chief-executive-officer" rel="noreferrer noopener">ongoing financial struggles</a>.
Joyner, previously president of CVS Caremark and an executive vice president at the company, steps into this leadership role as Roger Farah, CVS&#8217;s board chairman, assumes the executive chair position.
The company warned that its upcoming third-quarter earnings, set for release on November 6, will miss Wall Street projections.
The company revealed preliminary third-quarter 2024 adjusted EPS of $1.05-$1.10, compared to the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.70</a>. Analysts expect sales of $92.73 billion.
Results for the third quarter include charges to record premium deficiency reserves (PDRs), primarily related to the company&#8217;s Medicare and Individual Exchange businesses inside its Health Care Benefits segment, of approximately&nbsp;$1.1 billion, which lowered third quarter 2024 Adjusted EPS by&nbsp;$0.63.
In the third quarter of 2024, CVS continued to experience medical cost trends over those projected in its prior outlook.
The Medical Benefit Ratio for the third quarter is currently expected to be approximately 95.2%, which includes a 220-basis point impact from the PDRs.
The company added, &#8221; In light of continued elevated medical cost pressures in the Health Care Benefits segment, investors should no longer rely on the company&#8217;s previous guidance.&#8221;
The pharmacy giant is also backing away from the fiscal year 2024 issued during the second-<a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40220306/cvs-health-reports-mixed-q2-earnings-lowers-2024-outlook-reshuffles-segment-management" rel="noreferrer noopener">quarter earnings release</a>.
The company&nbsp;reported second-quarter sales of $91.23 billion, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $91.51 billion</a>.&nbsp;Adjusted EPS of&nbsp;$1.83&nbsp;decreased from&nbsp;$2.21&nbsp;in the prior year, beating the consensus of $1.73.&nbsp;
In Q2 earnings, CVS Health revised its 2024 adjusted EPS guidance to $6.40-$6.65&nbsp;from at least&nbsp;$7.00&nbsp;versus consensus of $6.98.
CVS Health&nbsp;forecasted&nbsp;2024 sales of $369.0 billion—$372.0 billion versus a consensus of $368.876 billion at prior guidance of at least $369 billion.
The company expected a medical benefits ratio of 90.6% – 90.8% versus ~<a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40220306/cvs-health-reports-mixed-q2-earnings-lowers-2024-outlook-reshuffles-segment-management" rel="noreferrer noopener">89.8% expected earlier</a>.
The company is already struggling as the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health&#8217;s Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)&nbsp;Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)&nbsp;Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">price of insulin medications</a>.
As per an October report, CVS Health is also considering a major restructuring that could involve separating its&nbsp;retail <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41115344/cvs-health-mulls-split-of-retail-and-insurance-divisions-to-address-financial-challenges-report" rel="noreferrer noopener">and insurance businesses</a>.
These talks with financial advisers explore how a potential breakup would work, although no final decisions have been made yet.
Price Action: At last check on Friday, CVS stock was down 12.30% at $55.87 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41389304/abbott-labs-path-to-double-digit-earnings-growth-in-2025-this-analyst-is-optimistic" target="_blank" rel="noreferrer noopener">Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic</a></li>
</ul>
Image via Shutterstock

Large Cap

Guidance

Health Care

Management

General

Pharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $45 to $80.

CORT

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $80

Baird analyst David Rescott maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Outperform and raises the price target from $503 to $565.

Baird Maintains Outperform on Intuitive Surgical, Raises Price Target to $565

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) with a Neutral.

HC Wainwright & Co. Reiterates Neutral on Kezar Life Sciences

AVTR

Avantor Closes Previously Announced Divestiture Of Its Clinical Services Business  In A Transaction Valued At Approximately $650M, Company Sees $500M In After-tax Cash Proceeds And Reduction Of Approximately $50M In Capitalized Leases

SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares are trading higher Friday morning. On Thursday, the company filed a Form RW indicating that it has decided not to <a target="_blank" href="https://ir.sobrsafe.com/sec-filings/all-sec-filings/content/0001477932-24-006541/sobr_rw.htm" rel="noreferrer noopener">proceed </a>with the proposed public offering at this time.
The Commission has not declared the Registration Statement effective, and no securities have been sold in connection with the offering.
Recently, the company announced the pricing of a private placement with institutional investors, expected to<a href="https://www.benzinga.com/news/24/10/41231927/why-sobr-safe-stock-is-getting-hammered" target="_blank" rel="noreferrer noopener"> raise $8.2 million in gross proceeds</a>.
The company planned to issue 2.02 million units at $4.05 per unit, each consisting of one share of common stock or a pre-funded warrant, along with Series A and Series B warrants.
The proceeds were intended to be used for general corporate purposes and working capital. The private placement was expected to close by October 8, pending customary closing conditions.
Price Action: SOBR shares are up 116.3% at $17.20 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41397978" target="_blank" rel="noreferrer noopener">Hedge Fund Billionaire Daniel Loeb Bets On Trump Win, Singles Out This Recent Buy As Having &#8216;Significant Upside Potential&#8217;</a></li>
</ul>

Small Cap

SOBR

Why Is SOBR Safe Stock Rocketing On Premarket Friday?

Contracts

LASE

Laser Photonics Completes Dual Follow-On Sale To Deliver Two Additional CleanTech Industrial Roughening Laser 3050 Systems To Acuren

RBC Capital analyst Sean Dodge maintained a Buy rating on Privia Health Group (PRVA – Research Report) yesterday and set a price target of $28.00. ...

Privia Health Group (PRVA) Gets a Buy from RBC Capital

In a report released today, Sean Dodge from RBC Capital maintained a Buy rating on Privia Health Group (PRVA – Research Report), with a price targe...

RBC Capital Sticks to Their Buy Rating for Privia Health Group (PRVA)

J.P. Morgan analyst Lisa Gill maintained a Buy rating on Privia Health Group (PRVA – Research Report) on August 26 and set a price target of $27.00...

Privia Health Group (PRVA) Receives a Buy from J.P. Morgan

In a report released today, Jailendra Singh from Truist Financial reiterated a Buy rating on Privia Health Group (PRVA – Research Report). The comp...

Truist Financial Sticks to Their Buy Rating for Privia Health Group (PRVA)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 10/2/2024, According to Top Analysts

Morgan Stanley identifies 39 stocks likely to face tax loss selling pressure

Morgan Stanley's list of tax loss selling stocks

What's next for health insurers as Medicare finalizes 2025 Star Ratings?

KeyBanc sees hospitals beating/raising with Q3 earnings

As we head into the final months of 2024, economic conditions appear to be improving. The rate of inflation has slowed down nearly to the Fed's tar...

Humana or Privia: KeyBanc Selects the Superior Healthcare Service Stock to Buy

ADBE

ADUS

ALHC

APTV

ARCH

ARDT

ASTH

BIIB

CHRD

CIVI

DVAX

IIIN

INNV

IRDM

NBIX

NMRA

NVEE

PLAB

PRGO

PRVA

PTEN

RGEN

ROCK

SMPL

SPTM

TALO

USPH

XLRE

XPEL

Press Releases

Privia Health to Report Fourth Quarter and Full-Year 2023 Results on Tuesday, February 27

Privia Health Appoints Edward C. Fargis as General Counsel

Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results

Privia Health to Report First Quarter 2024 Results on Thursday, May 9

Privia Health Reports First Quarter 2024 Financial Results

Privia Health to Participate in the William Blair Growth Stock Conference

Privia Receives HFMA's MAP Award for High Performance in Revenue Cycle for Performance Year 2023

Privia Health to Report Second Quarter 2024 Results on Thursday, August 8

Privia Health Reports Second Quarter 2024 Financial Results

Privia Health to Report Third Quarter 2024 Results on Thursday, November 7

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Privia Health Gr

Notizie

Ultime notizie per Privia Health Gr (NASDAQ:PRVA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO